Investors should consider voting on the proposals, particularly the equity plan expansion and share authorization increase which could lead to future dilution. Monitor for any insider trading activity around these governance changes.
RLMD drugs
RLMD drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 20 $7.37entry
- T+1 · 7mo ago −3.12%α −2.47% · $7.14
- T+5 · 7mo ago −4.61%α −5.53% · $7.03
- T+20 · 6mo ago −13.98%α −18.18% · $6.34
- T+60 · 4mo ago −15.74%α −22.52% · $6.21
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Relmada Therapeutics is holding its 2026 annual meeting where shareholders will vote on four key proposals: electing two Class II directors, ratifying the appointment of CBIZ CPAs P.C. as auditors, increasing the number of shares available under its equity incentive plan by 3 million, and increasing its authorized common stock from 150 million to 200 million shares. The filing is a routine proxy statement with no material financial data disclosed.
Key Financial Metrics
Key Facts
- Relmada Therapeutics is holding its 2026 annual meeting
- Shareholders will vote to elect two Class II directors: Charles J. Casamento and Sergio Traversa
- Proposal to ratify CBIZ CPAs P.C. as independent auditors for 2026
- Proposal to increase shares available under the 2021 Equity Incentive Plan by 3 million
- Proposal to increase authorized common stock from 150 million to 200 million shares
Financial Impact
3 million additional shares for equity incentives, increase in authorized shares from 150M to 200M
Risk Factors
- Potential dilution from increased share authorization and equity incentives
- Governance risks if shareholder approval is not obtained for key proposals
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001213900-26-045194 |
| Document: 0001213900-26-045194-index-headers.html | 0001213900-26-045194 |
| Document: 0001213900-26-045194-index.html | 0001213900-26-045194 |
| Document: 0001213900-26-045194.txt | 0001213900-26-045194 |
Track record
11 reports on RLMD
2 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +38.81% at T+60 after the May 13, 2026 report. 2 of 3 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Bearish 5/10 Entry $3.54 Now $3.61 −1.98% settles Dec 15
- Nov 16, 2026today 8-K Neutral 3/10 Entry $4.16 Now $3.61 −13.23% settles Dec 15
- Nov 12, 20264d ago 8-K Neutral 4/10 Entry $4.21 Now $3.61 −14.25% settles Dec 14
- Sep 11, 20269w ago Insider Cluster Bullish 6/10 Entry $4.52 to $3.39 Now $3.61 −20.13% ▼ −25.00% −26.87% vs SPY
- May 13, 202626w ago S-3ASR Bearish 6/10 Entry $7.42 to $6.65 Now $3.61 +51.35% ▲ +10.38% +9.52% vs SPY
- May 12, 202626w ago 8-K Neutral 4/10 Entry $7.49 to $6.52 Now $3.61 −51.80% ▼ −12.95% −12.34% vs SPY
- Apr 17, 202630w ago DEFA14A Neutral 3/10 Viewing Entry $7.37 to $6.34 Now $3.61 −51.02% ▼ −13.98% −18.18% vs SPY
- Apr 3, 202632w ago S-3 Neutral 3/10 Entry $6.90 to $7.41 Now $3.61 −47.68% ▲ +7.39% −1.59% vs SPY
- Mar 19, 202634w ago Press Release Bullish 8/10 Entry $6.07 to $7.37 Now $3.61 −40.53% ▲ +21.42% +12.10% vs SPY
- Mar 12, 202635w ago Press Release Neutral 3/10 Entry $6.15 to $7.29 Now $3.61 −41.30% ▲ +18.54% +16.56% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers